Core Viewpoint - Phibro Animal Health reported strong financial performance in the second quarter, with significant revenue and adjusted net income growth, leading to raised guidance for future financial metrics [2][5]. Financial Performance - The company achieved 21% revenue growth and 60% growth in adjusted net income, generating $94 million in revenue for the quarter [2][5]. - Following a robust first half, the company raised its guidance for revenue, EBITDA, and adjusted net income, reflecting positive investor feedback [1][5]. Business Segments - Continued growth was noted in vaccines (13% growth) and nutritional specialties (9% growth) for the quarter [1]. - The legacy Medicated Feed Additives (MFA) business experienced a 5% decline due to order timing but would have grown approximately 3% when normalized [1]. Strategic Focus - Management is prioritizing higher-margin growth in vaccines and nutritional specialties, aiming for mid-to-high single-digit growth and margin expansion [3][7]. - The integration of the Zoetis MFA portfolio is progressing well, with expectations for MFA growth to be flat to low-mid single digits long-term, targeting outperformance post-fiscal 2027 [4][6]. Market Dynamics - Strong end-market demand for animal-based protein and effective execution across segments contributed to recent performance [9]. - Consumer demand for meat, eggs, and dairy remains robust despite inflation, with demographic trends favoring high-quality protein consumption [10]. Competitive Positioning - Phibro is positioned as a strong competitor in the MFA market, likely ranking second globally, with key competitors including Elanco and Huvepharma [14]. - The company is also focusing on pricing adjustments during the integration of the Zoetis MFA portfolio to enhance margins [15]. Companion Animal Business - The company has launched a new product, Restoris, in the companion animal segment, which is expected to grow significantly over time [16]. - Management plans to reinvest profits from this segment while maintaining fiscal conservatism [16]. Leadership Transition - Dani Bendheim is set to become CEO later this year, with a focus on continuity in strategy and operations [3][17]. - The broader management team will remain in place, ensuring stability during the transition [18].

Summary of Phibro Animal Health Conference Call Company Overview - **Company**: Phibro Animal Health (NasdaqGM: PAHC) - **Date**: February 26, 2026 - **Key Speakers**: Dani Bendheim (Chief Strategy Officer and incoming CEO), Glenn David (CFO), Larry Miller (COO) Key Points Financial Performance - **Fiscal 2Q Results**: - Revenue growth of **21%** year-over-year - Adjusted net income growth of **60%** - Total revenue for the quarter was **$94 million** [5][6] - **Legacy MFA Business**: - Experienced a **5% decline** due to timing of orders from a major customer, but normalized growth was around **3%** [5][6] - **Vaccine Portfolio**: - Grew by **13%** - **Nutritional Specialty**: - Grew by **9%** - **Guidance Update**: - Confidence to raise guidance for revenue, EBITDA, and adjusted net income for the year [6][7] Strategic Developments - **Zoetis Acquisition**: - Integration of the Zoetis Medicated Feed Additive (MFA) portfolio is progressing well, expected to enhance overall business [11][12] - Anticipated growth in MFA portfolio to be flat to low mid-single digits in the long term, with vaccines and nutritional specialties expected to grow mid to high single digits [12][13] - **Market Dynamics**: - Strong demand for animal-based protein consumption is driving growth in the livestock market [20][24] - The company is focusing on building relationships with customers and addressing new disease challenges [21][22] Competitive Landscape - **Positioning**: - Phibro is positioned as a strong competitor in the MFA market, likely the **number two globally** [47][48] - Competes with Elanco and Huvepharma in the MFA space, while facing more competition in vaccines from Zoetis, Merck, and others [48][49] - **Market Share**: - Growth in sales suggests potential market share expansion, particularly through innovation and addressing emerging diseases [52] Pricing Strategy - **Pricing Power**: - The company has identified opportunities for price adjustments, particularly in acquired products, without significant volume drops [54][56] - Future price increases are expected to be low single-digit as products mature [58] Companion Animal Business - **Growth Potential**: - Companion animal products like Restoris and Regensa are showing strong growth, with plans to reinvest profits into this segment [61][62] - **Long-term Strategy**: - Aiming to establish the companion animal segment as a fourth pillar alongside MFAs, nutritional specialties, and vaccines [63] Margin Expansion - **Drivers of Margin Growth**: - Positive mix dynamics, growth in higher-margin products, and initiatives from the Phibro Forward program are contributing to margin expansion [65][66] - **Future Outlook**: - The company expects to continue driving income growth faster than revenue, with Phibro Forward hitting its peak in fiscal year 2027 [67] Leadership Transition - **CEO Transition**: - Dani Bendheim will take over as CEO, emphasizing continuity in strategy and operations [70][72] Additional Insights - **Cultural Integration**: - The integration of Zoetis employees and culture has been positive, with excitement about the new direction [40][41] - **Customer Reception**: - Positive feedback from customers regarding the expanded product portfolio and support [44][45] This summary encapsulates the key points discussed during the Phibro Animal Health conference call, highlighting financial performance, strategic developments, competitive positioning, pricing strategies, and future outlook.

Financial Performance - Consolidated net sales for Q2 2026 were $373.9 million, reflecting a 21% increase year-over-year [12] - Animal health segment sales grew by 26%, while Mineral Nutrition increased by 9%, and Performance Products declined by 10% [12][14] - Adjusted EBITDA increased by 41% to $82.2 million, driven by the new MFA business and improved gross profit [15][18] - Adjusted net income rose by 60%, and adjusted diluted EPS increased by 58% [14] Business Segment Performance - Animal health segment net sales reached $290 million, a 26% increase, with the new MFA business contributing $94.1 million [14][15] - Nutritional specialties saw a 9% increase in net sales due to higher North American demand for dairy [15] - Vaccine net sales grew by 13%, driven by poultry products in Latin America and higher international demand [15] - Mineral nutrition segment net sales were $68.9 million, a 9% increase, while Performance Products segment sales decreased by 10% to $15 million [15][16] Market Insights - The protein markets are experiencing strong demand, particularly in beef, chicken, pork, turkey, dairy, and eggs [32] - Favorable feed costs are helping maintain margins, with expectations of some shifts in trade due to tariffs and disease outbreaks [32] - The company is well-diversified across livestock species and geographic markets, enhancing its competitive position [33] Company Strategy and Direction - The company is focused on sustainability and profitability, emphasizing better gut health and improved feed conversion [11] - The Phibro Forward strategy aims to drive future growth through R&D and digital capabilities [11][50] - The leadership transition is seen as an opportune moment, with continuity in management and a strong cultural foundation [10] Management Commentary - Management expressed confidence in the company's direction and the strength of its business, citing positive feedback from customers and strong alignment among leadership [7][9] - The integration of the MFA portfolio is yielding positive results, with management noting strong performance and customer partnerships [5][8] Other Important Information - The company raised its full-year guidance for fiscal year 2026, with net sales expected to be between $1.45 billion and $1.5 billion [18] - The gross leverage ratio was 3.1x, and net leverage ratio was 2.8x at the end of the quarter [17] Q&A Session Summary Question: What are the main drivers of gross margins this quarter? - Management highlighted successful pricing strategies, positive product mix, and internal focus on higher-margin products as key drivers [22][23] Question: Can you elaborate on the guidance update and what is performing better than expected? - Management noted strong revenue performance, effective integration of the acquired portfolio, and improved mix as factors contributing to the positive outlook [24][25] Question: What impact did customer timing have on the MFA business? - Management explained that fluctuations in customer inventory levels affected sales, but improvements are expected in the next quarter [28][29] Question: How sustainable is the current demand in livestock markets? - Management expressed confidence in the sustainability of demand due to diversification and favorable feed costs [32][33] Question: Are there share gains from the stronger combined portfolio? - Management confirmed strong performance in poultry and swine segments, indicating share gains due to a more complete product offering [35][41] Question: Update on the Phibro Forward initiative? - Management stated that Phibro Forward continues to be a significant growth driver, with expected contributions accelerating through fiscal year 2026 [48][50]

Summary of Fibro Animal Health Conference Call Company Overview - **Company Name**: Fibro Animal Health - **Ticker Symbol**: PAHC - **Founded**: 1946 - **Employees**: Approximately 2,300 - **Manufacturing Plants**: 6 to 18 worldwide - **Product Registrations**: About 22,000 - **Global Reach**: Customers in approximately 100 countries - **Fiscal Year End**: June 30 Industry Context - **Sector**: Food Animal Health - **Market Demand**: The global population is expected to reach 10 billion in the next couple of decades, necessitating a 70% increase in animal-based protein production [4][4] - **Sustainability Focus**: The company aims to produce more with fewer natural resources, emphasizing animal health and welfare [4][4] Financial Performance - **Fiscal Year 2024 Revenue**: Achieved $1 billion before the acquisition of Zoetis' medicated feed additive business [6][6] - **Pro Forma Revenue Post-Acquisition**: Expected to reach approximately $1.4 billion [15][15] - **EBITDA Margins**: Targeted low 20% margins; currently achieving mid to high 20% margins on the acquired business [15][15] - **Sales Growth**: Legacy business sales up 8% year-over-year; EBITDA up 26% [21][21] - **Guidance for Fiscal Year**: Net sales projected between $1.26 billion and $1.29 billion, with EBITDA between $177 million and $183 million [29][29] Acquisition Insights - **Acquisition of Zoetis MFA Business**: - Completed integration process deemed successful [14][14] - Acquisition was strategic, enhancing revenue diversification and market presence [11][11] - Introduced new geographies and balanced product offerings across species [16][16] - Sales from Zoetis products in the first five months totaled $113 million, with a full-year estimate of $350 million [30][30] Product Portfolio - **Core Product Categories**: - **Medicated Feed Additives**: Includes antimicrobials, antioxidants, and anthelmintics [22][22] - **Nutritional Specialties**: Non-medicated products aimed at maintaining animal health [25][25] - **Vaccines**: Primarily poultry vaccines, including custom autogenous vaccines [27][28] Market Trends and Opportunities - **Geographic Expansion**: Increased focus on Europe, which previously represented only 8% of the Zoetis business [18][18] - **Species Focus**: Strengthened presence in beef and swine markets, particularly in the U.S. [42][42] - **Sustainability Market**: Recognized as a growing opportunity, particularly in dairy, with potential for technology solutions to address environmental concerns [59][60] Challenges and Future Outlook - **Headwinds**: Anticipated tariffs could impact EBITDA by $5 million to $10 million [34][34] - **Transformation Initiative**: "Fiber Forward" aims to enhance income growth through cost and sales strategies [34][34] - **Long-term Growth**: Positive outlook for continued growth across all business lines, with a focus on vaccines, nutritional specialties, and medicated feed additives [32][32] Conclusion Fibro Animal Health is positioned for significant growth following its acquisition of Zoetis' MFA business, with a strong focus on sustainability and expanding its market presence across various species and geographies. The company is optimistic about its financial performance and future opportunities in the animal health sector.

Financial Performance and Key Metrics - Total sales increased by 32% year over year, reaching $347.8 million, with adjusted EBITDA rising by 85% and adjusted diluted EPS more than doubling [6][11][10] - GAAP net income and diluted EPS saw significant increases, driven by the integration of the new MFA business and improved gross margins [11][12] - Adjusted EBITDA for the third quarter increased by $25.2 million, reflecting strong sales growth and improved operating leverage [12][10] Business Segment Performance - The Animal Health segment led with a 42% revenue growth, contributing $258.4 million in net sales [12][11] - Newly integrated MSA and other products within Animal Health saw a 68% increase in sales, while legacy MSA and other products declined by 3% [7][13] - Nutritional Specialties maintained an 8% revenue growth, while Performance Products posted a remarkable 28% increase [7][15] Market Data and Key Indicators - The company anticipates some pressure on certain inputs and markets in the range of $5 million to $10 million due to tariffs in fiscal year 2026, but believes it is well-positioned to manage these impacts [9][21] - The overall performance reflects strong execution and operational excellence, which are central themes of the company's Fiber Forward strategy [7][8] Company Strategy and Industry Competition - The Fiber Forward strategy emphasizes disciplined operations and continuous improvement, contributing to the company's performance and ability to navigate external challenges [8][9] - The company is focused on unlocking additional areas of revenue growth and cost savings through various initiatives, including potential price increases and expanded product offerings [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering strong income growth in fiscal year 2026, driven by continued strong performance in the legacy business and a full year of revenue contribution from the Zoetis MFA portfolio [21][10] - The company does not expect any material impact from the evolving tariff environment on its financial results for the remainder of fiscal year 2025 [9][21] Other Important Information - The company generated $49 million of positive free cash flow for the twelve months ended March 31, 2025, with cash and cash equivalents totaling $70 million at the end of the quarter [16][17] - The gross leverage ratio was 3.0x, and the net leverage ratio was 2.7x at the end of the third quarter [17] Q&A Session Summary Question: Can you elaborate on the company's exposure to upcoming pharma tariffs and potential mitigation strategies? - Management indicated that most manufacturing is done in the U.S., with some inputs sourced from other markets. They have built inventory, switched suppliers, and announced price increases to mitigate tariff impacts [23][26] Question: What drove the slower growth in the Medicaid fee added business? - The slower growth was attributed to the timing of orders from larger customers and a difficult comparative quarter from the previous year, but overall demand remains strong [27][28] Question: What factors are driving the increase in guidance for EBITDA and EPS? - The increase is driven by a favorable mix, strong performance in the vaccine portfolio, and improved margins from the Zoetis MFA portfolio [32][33] Question: Can you provide more details on the specific products affected by tariffs? - The impact is primarily from inputs subject to general tariffs rather than specific products from China, with ongoing efforts to manage costs and supplier negotiations [36][37] Question: Is the company lobbying for exceptions from potential pharma tariffs? - Management confirmed involvement in lobbying efforts for exceptions, emphasizing the importance of these products in the food supply chain [40][41]